drugset / Trial / NCT03850522
PD-L1 Peptide Vaccination in High Risk Smoldering Multiple Myeloma
NaSingle-groupOpen-labelTreatment
Summary
This study is evaluating a new vaccine against PD-L1 as a possible treatment for high-risk smoldering multiple myeloma.
Timeline
- Start
- 2019-02-18
- Primary completion
- 2021-03-10
- Completion
- 2021-03-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IO103 | Vaccine | 100 ug | Subcutaneous |
| Background | incomplete Freund's adjuvant | Other / unclassified | — | Subcutaneous |